What is CNTX's dilution risk score?

CNTX has a latest available DilutionScore record of 40/100, categorized as medium dilution risk by the DilutionWatch scoring model. DilutionWatch displays SEC filing and dilution indicators for CNTX, including shelf registrations, ATM offerings, warrant exercises, PIPE deals, and reverse split signals when detected in source data.

What SEC filings does DilutionWatch track for CNTX?

DilutionWatch tracks 25 SEC filing types for CNTX including S-3 shelf registrations, 424B prospectuses (ATM offerings), S-1 registration statements, 8-K material events, warrant exercise notices, convertible note agreements, and Form 4 insider transactions. Alerts are delivered via email within minutes of a filing appearing on EDGAR.

How does stock dilution affect CNTX shareholders?

Stock dilution occurs when a company issues new shares, reducing the ownership percentage of existing shareholders. For CNTX, common dilution events include at-the-market (ATM) stock offerings, shelf registration drawdowns, warrant exercises, and convertible note conversions. Each event increases the share count and can pressure the stock price lower.

Is DilutionWatch free for CNTX tracking?

DilutionWatch provides a free tier that shows DilutionScores and basic filing history for CNTX. Premium plans ($19.95/month Basic, $39.95/month Premium) unlock real-time email alerts, the full Pulse™ feed, advanced dilution forecasts, and access to all 10,000+ tracked tickers.

CNTX Dilution Risk Score: 40/100 (MEDIUM)

Score Breakdown

📋 Offering Ability

💰 Cash Runway

📊 Float Risk

⚠️ Warrant Exposure

🔄 Convertible Debt

Dilution Forecast

☀️

Clear

No significant dilution signals

model est. 12%

🔄 Reverse Split model est. 15%

• 52-week low $0.52 has breached $1

📜 Warrant Exercise model 15%

• Warrant overhang: 10.0% of shares outstanding

🔔 Track CNTX — Get forecast alerts →

Market Data

Market Cap$28.02M

Shares Outstanding91.88M

Float42.82M

Cash$42.99M

Debt$282.4K

Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

Field	Current Value	Basis
DilutionScore	40/100	DilutionWatch score record
Shares Outstanding	91.88M	Verified float table or market cache
Public Float	42.82M	Verified float table or market cache
Market Cap	$28.02M	Market data cache
Cash Runway	19.4 months	DilutionWatch score inputs
Shelf Capacity	None in current score inputs	SEC-derived dilution fields
ATM Capacity	None in current score inputs	SEC-derived dilution fields
Outstanding Warrants	9.16M	SEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 1, SC 13G 1, SC 13G/A 3, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 13.6% shares (2026Q1 vs prior)

61 institutional holders · 82.93M shares

#1 MPM BIOIMPACT LLC 10.68M shares

#2 Avidity Partners Management LP 10.00M shares

#3 Nextech Invest, Ltd. 7.42M shares

+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest4.71M

Days to Cover4.0

% of Float11.0%

FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-08-05

xbrl XBRL CONVERTIBLE 2023-03-22

SC 13G/A BENEFICIAL OWNERSHIP 2026-08-14

SC 13G/A BENEFICIAL OWNERSHIP 2026-08-12

SC 13G/A BENEFICIAL OWNERSHIP 2026-07-31

Full SEC filing analysis available with free account →

Recent News

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 Yahoo Finance · Sep 09, 2026

Context drops bispecific T-cell engager on cost-cutting initiative Pharmaceutical Technology · Aug 07, 2026

Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, GlobeNewswire · Aug 07, 2026

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress GlobeNewswire · Aug 05, 2026

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 10, 2026

Context Therapeutics Joins Russell 2000, Russell 3000 Indexes MT Newswires · Jul 06, 2026

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes Yahoo Finance · Jul 06, 2026

Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullis Yahoo Finance · Jul 05, 2026

Factual CNTX Dilution Snapshot

Context Therapeutics Inc. (CNTX) has a DilutionScore of 40/100, rated Medium dilution risk. Score date: October 13, 2026.

Stored outstanding warrants: 9.2M.
Recent SEC activity tracked for CNTX: SC 13G/A on 2026-08-14; SC 13G/A on 2026-08-12; xbrl on 2026-08-05.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

CNTX's DilutionScore is currently 40/100 (Medium risk), with 2 score changes tracked over 89 days. The score deteriorated from 41/100 (Medium risk).

Period	Score	Risk Level	Duration
Sep 28 – Oct 13, 2026	40/100	MEDIUM	16 days
Aug 14 – Sep 27, 2026	41/100	MEDIUM	44 days
Jul 16 – Aug 13, 2026	36/100	MEDIUM	29 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Track CNTX Dilution Risk in Real-Time

DilutionWatch monitors SEC filings 24/7 and alerts you the moment CNTX files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.

Start Tracking CNTX — Free

Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously